ZHOU Zhiwang, Ph.D, Professor
Advisor Type: Master's Advisor
E-mail: zhouzw@ncu.edu.cn
Place of Origin: Daye, Hubei
Courses Taught: Medicinal Chemistry of Natural Products, Frontiers in Pharmacy
Research Areas
1. R&D of Innovative Drugs and Functional Products Derived from Chinese Herbal Medicines, Edible and Medicinal Plants, and Natural Medicines
2. Diversity-Oriented Molecular Editing and Druggability Research of Bioactive Natural Products
3. R&D of New TCM Prescriptions and Classic Famous Prescriptions Based on Traditional TCM Theory
Education
1998.09-2002.06: Department of Applied Chemistry, East China University of Technology, B.Sc.
2002.09-2005.06: College of Chemistry, Sichuan University, M.Sc.
2005.09-2008.06: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Ph.D.
Academic Services
² Expert Reviewer for the National Natural Science Foundation of China
² Anhui Provincial Natural Science Foundation Peer Review Expert
² Industrial Expert in TCM and Biomedicine for Jiangxi Province
² Standing Committee Member of the Pharmaceutical Chemistry Committee, Jiangxi Pharmaceutical Association
Professional Experience
2008.09~2014.12: Lecturer, School of pharmacy, Nanchang University
2014.12~2023.12: Associate Professor, School of pharmacy, Nanchang University2023.12~: Professor, School of pharmacy, Nanchang University
Awards & Honors
Nanchang University Teaching Excellence Award in 2020
Nanchang University Teaching Excellence Award in 2021
Nanchang University Teaching Excellence Award in 2022
Nanchang University Teaching Excellence Award in 2023
Nanchang University Teaching Excellence Award in 2024
Nanchang University Teaching Excellence Award in 2025
Grants & Fundings
1. National Natural Science Foundation of China (NSFC), “The Discovery and Anti-T2DM Bioactivity of a-Pyrones-Type GLUT4 Translocation Agonist from the Cryptocarya Genus Plants”, RMB 330,000 (2023.01-2026.12), Principal Investigator
2. National Natural Science Foundation of China (NSFC), “The Chemical Constituents and Anti-Tumor Activity of Three Artocarpus Plants”, RMB 500,000 (2014.01-2017.12), Principal Investigator
3. National Natural Science Foundation of China (NSFC), “Synthesis and Modification of Novel Natural Peptide Deformylase Inhibitors”, RMB 200,000 (2010.01-2012.12), Principal Investigator
4. Jiangxi Provincial Natural Science Foundation, “Construction of a Natural Product-Like Library of Artocarpus Prenylflavonoids Based on a Diversity-Oriented Synthesis Strategy and Screening for Their Anti-Tumor Activity”, RMB 50,000 (2014.01-2016.12), Principal Investigator
5. Jiangxi Provincial Natural Science Foundation, “Construction of a Natural Product-Like Library through Structure Diversity Modification of Euphorbia Diterpenoids and Screening for Multiple Pharmacological Activities”, RMB 50,000 (2015.01-2017.12), Principal Investigator
6. Jiangxi Provincial Natural Science Foundation, “Synthesis and Modification of Novel Natural Peptide Deformylase Inhibitors”, RMB 10,000 (2010.01-2012.12), Principal Investigator
7. Jiangxi Provincial Education Department Project, “Asymmetric Synthesis of the PDF Inhibitor Fumimycin”, RMB 20,000 (2013.01-2015.12), Principal Investigator8. Open Fund of the Key Laboratory of Modern Chinese Herbal Formulations, Ministry of Education, Jiangxi University of Chinese Medicine, “Discovery of Anti-Tumor Chemical Constituents from Selaginella tamariscina and Study on Their Mechanism of Action”, RMB 40,000 (2019.01-2020.12), Principal Investigator9. Open Fund of the Key Laboratory of Modern Chinese Herbal Formulations, Ministry of Education, Jiangxi University of Chinese Medicine, “Discovery and Anti-Tumor Evaluation of Prenylated Stilbenes from the Medicinal Plant Artocarpus chama (Moraceae)”, RMB 30,000 (2022.01-2023.12), Principal Investigator
Selected Publications
[1] Wang XN, Kuang XD, Wang Y, Sun P, He XR, Peng YA, Liu LH, Gu JL, Gan LS, Wang XN, Shu* JC, Zhou ZW*. a-Pyrones with glucose uptake-stimulatory activity from the twigs of Cryptocarya wrayi [J]. Fitoterapia 2022, 158, 105144.
[2] Liu YL, Wang Y, He XR, Gan LS*, Xu F, Xu YJ, Wang XN, Shen T, Zhou ZW*. Two new isoquinoline alkaloids from Cryptocarya wrayi and their biological activities [J]. Fitoterapia 2022, 156, 105086.
[3] Xiong Y, Liu X, Xu LY, Lin QM, He XR, Zhou ZW*. Artopithecin K, a new phenolic derivative with tyrosinase inhibitory activity from Artocarpus pithecogallus [J]. J. Chem. Res. 2020, 44 (9-10), 524-526.
[4] Lin QM, Wang Y, Yu JH, Liu YL, Wu X, He XR, Zhou ZW*. Tyrosinase inhibitors from the leaves of Eucalyptus globulus [J]. Fitoterapia, 2019, 139, 104418.
[5] Xu LY, Liu X, Lin QM, Wang Y, He XR, Zhou ZW*. Prenylflavanones and lignans from the twigs of Artocarpus Pithecogallus [J]. Magn. Reson. Chem. 2019, 57, 506–511.
[6] He XR, Xu LY, Jin C, Yue PF, Zhou ZW, Liang XL*. Tamariscinols U-W, new dihydrobenzofuran-type norneolignans with tyrosinase inhibitory activity from Selaginella tamariscina [J]. Phytochemistry Lett, 2019, 34, 79–83.
[7] Liu X, Kuang XD, He XR, Ren G, Wang Y, Xu LY, Feng LH, Wang B, Zhou ZW*. Prenylflavonoids from the Twigs of Artocarpus nigrifolius [J]. Chem. Pharm. Bull. 2018, 66, 434–438.
[8] Wang Y, Xu LY, Liu X, He XR, Ren G, Feng LH, Zhou ZW*. Artopithecins A–D, Prenylated 2-Arylbenzofurans from the Twigs of Artocarpus pithecogallus and Their Tyrosinase Inhibitory Activities [J]. Chem. Pharm. Bull. 2018, 66, 1199–1202.
[9] Liu X, Wang Y, Kuang XD, Ren G, He XR, Feng LH, Wang B, Zhou ZW*. Isolation and Identification of Chemical Constituents from Artocarpus nigrifolius[J]. Chinese Journal of Experimental Traditional Medical Formulae. 2018, 24, 78–87.
Patent Publication
[1] Zhou ZW, Xu LY, Lin QM, Liu YL, Wang XN. Preparation and Use of a Phenolic Acetal Derivative. Chinese Patent: ZL 2020 1 0102158.5.
[2] Zhou ZW, Wang Y, Liu YL, Wang XN, Jiang TT, Tang YY. Preparation and Use of a Class of α-Pyrone Derivatives with Hypoglycemic Effects. Chinese Patent: ZL 2021 1 1390046.5
[3] Zhou ZW, Wang Y, Liu YL, Wang XN, Jiang TT, Tang YY. Preparation and Use of a Class of Isoquinoline Alkaloids with Quinone Reductase Inducing Activity. Chinese Patent: ZL 2021 1 1390216.X.
[4] Lin QM, Jiang TT, Tang YY, Zhou ZW. Preparation and Use of a Class of Phenolic Compounds with α-Glucosidase Inhibitory Activity. Chinese Patent: No. 202210947889.9.
Cn
